Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

David Smadja, ESCRS 2019 – Nanoparticles in drug delivery

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 27th 2019

We met with David Smadja (Shaare Zedek Medical Center, Jerusalem, Israel) to talk about the challenges of nanoparticle design and the challenges in drug delivery at ESCRS 2019.

Questions:
1. What are the limitations of current methods of ocular drug delivery? (0:04)
2. What challenges that have to be overcome with nanoparticles in order to improve drug delivery? (1:48)
3. What factors should be considered when optimising nanoparticle design? (3:29)
4. What other innovations would you like to highlight? (5:42)

Support: No funding was received in the production of this video.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup